How to Address Data Consistency Challenges in EU MDR Submissions: A CAPTIS® Perspective

Introduction

Data consistency is one of the most persistent and most underestimated challenges in EU MDR submissions. Across Clinical Evaluation Reports (CERs), Post-Market Surveillance (PMS) documentation, Post-Market Clinical Follow-up (PMCF) deliverables, and Technical Documentation, even small discrepancies can trigger Notified Body questions, extend review timelines, and weaken confidence in an otherwise robust submission package.

CAPTIS®, Celegence’s AI-powered regulatory platform, was built specifically to address this challenge by creating a structured, traceable, and controlled documentation environment for medical device manufacturers.

This article explores the root causes of data consistency issues, why they matter during MDR conformity assessment, and how CAPTIS® helps regulatory and medical writing teams maintain alignment across the entire documentation lifecycle.

The Data Consistency Challenge Under EU MDR

EU MDR compliance demands a volume of interconnected evidence that few manufacturers anticipated when transitioning from MDD. A single device may require a Clinical Evaluation Plan and Report (CEP/CER), a Post-Market Clinical Follow-up (PMCF) Plan and Report, a Post-Market Surveillance (PMS) Report, a Periodic Safety Update Report (PSUR), and a Summary of Safety and Clinical Performance (SSCP), all of which must align on device description, clinical claims, benefit-risk conclusions, and adverse event data.

The challenge is that this data rarely flows from a single controlled source. Literature searches, adverse event databases, complaint records, and clinical study outcomes are gathered across different systems and time periods. When medical writing teams manage these inputs manually, through spreadsheets, shared folders, or disconnected document templates, inconsistencies accumulate. The benefit-risk ratio cited in the CER may not align with the safety signal trends documented in the latest PSUR. An indication statement in the SSCP may subtly differ from the one used in the clinical evaluation plan. These are precisely the kinds of discrepancies that Notified Body reviewers identify.

Moreover, Notified Bodies and MDCG guidance require transparent, reproducible Systematic Literature Review (SLR)/ State of the Art (SoTA) outputs with direct traceability from clinical claims to source data, and inconsistencies across documents are treated as systemic quality gaps, not editorial errors.

Why Notified Bodies Focus on Consistency and Traceability

Under EU MDR, consistency is closely linked to traceability. Notified Bodies expect manufacturers to demonstrate that clinical claims, risk assessments, PMS findings, PMCF outputs, and benefit-risk conclusions are supported by the same underlying evidence and remain aligned throughout the product lifecycle.

For example:

• Clinical claims described in the CER should be supported by the State of the Art (SoTA) assessment and literature evidence.
• PMCF findings should reinforce or update conclusions documented in the CER.
• PMS trend analysis and vigilance data should align with benefit-risk evaluations presented in the PSUR.
• Information presented in the SSCP should remain consistent with approved technical documentation.

When inconsistencies emerge between these documents, reviewers may interpret them as indicators of broader quality system weaknesses rather than isolated editorial issues.

Where CAPTIS® Changes the Equation

CAPTIS® was developed by Celegence in close collaboration with its own experienced medical writing teams, professionals who face these documentation challenges daily. Rather than offering a generic document management system, CAPTIS® is purpose-built for the regulatory workflows that EU MDR and IVDR demand. Its architecture addresses data consistency at the source, through several interconnected capabilities.

The CAPTIS® platform provides features such as a data dictionary that captures key device, clinical, and surveillance data once, then auto-fills this information consistently across all related reports. This eliminates the manual transcription errors that typically arise when information must be reproduced across multiple document templates. A change to a device description or a safety update is reflected uniformly, not piecemeal.

CAPTIS® also integrates directly with major literature and adverse event databases, including PubMed, Google Scholar, FDA MAUDE, and TPLC. Automated literature searches, metadata capture, and duplicate detection mean that the evidence base underpinning clinical claims are gathered systematically and reproducibly, a non-negotiable requirement under Notified Body review expectations. The platform’s SoTA workflow ensures that state-of-the-art evidence is structured, version-controlled, and directly traceable to the documents it informs.

Creating a Single Source of Truth

One of the primary causes of inconsistency is the duplication of information across multiple documents. CAPTIS® reduces this risk by establishing a centralized data foundation that serves as a single source of truth for critical device, clinical, and surveillance information.

By maintaining structured and controlled data objects, manufacturers can ensure that updates made to core information are reflected consistently throughout the documentation ecosystem, reducing manual effort and minimizing the risk of conflicting content.

Results Delivered Through Structured Automation

In internal CAPTIS® project evaluations, medical writing teams observed measurable efficiency improvements through automated evidence management and data reuse capabilities:

• Up to 62% reduction in time spent on data gathering activities
• 100% elimination of duplicate literature screening effort through automated duplicate detection

These efficiencies allow regulatory teams to focus more time on scientific evaluation, clinical interpretation, and quality review activities rather than administrative document management.

AI-Powered Consistency with CAPTIS® Copilot

The platform’s AI layer, CAPTIS® Copilot, takes consistency a step further by applying large language models (LLMs) to data extraction and content generation in a compliance-appropriate way. Rather than replacing medical writers, CAPTIS® Copilot augments their work: surfacing relevant evidence, generating structured literature summaries, and flagging content that requires human review. The result is documentation that is not only faster to produce but demonstrably more consistent in its structure, terminology, and evidential linkage across the submission package.

Celegence’s own medical writing teams use CAPTIS® Copilot in live regulatory projects, which means the AI capabilities are shaped by real-world MDR compliance demands, not theoretical use cases. This practical grounding is reflected in how the platform handles edge cases: complex device classifications, combination products, and legacy device transitions from MDD.

Collaboration and Auditability Built In

Data consistency is not only a data architecture problem, it is also a process problem. CAPTIS® addresses this with built-in collaborative review workflows that allow medical writers, reviewers, and regulatory managers to work simultaneously on documents, tag team members on specific sections, and manage sequential review steps within a single platform. This structured review process reduces the likelihood of version conflicts and ensures that final submission documents reflect consolidated, approved content rather than the last person to save the file.

Every action within CAPTIS® is captured in a centralised repository with version history and a full audit trail. For Notified Body submissions, this auditability is not incidental, it is a substantive demonstration that the documentation lifecycle has been managed with the rigour that EU MDR expects of a functioning quality management system.

Beyond version control, CAPTIS® strengthens traceability by maintaining a documented history of data updates, literature reviews, content approvals, and reviewer comments. This creates a transparent record of how conclusions were developed and maintained throughout the lifecycle of the device.

Practical Steps Manufacturers Can Take Today

For manufacturers who are yet to adopt a platform like CAPTIS®, the first priority is to map the data dependencies across their existing MDR document set. Understanding which upstream data sources feed which document sections is the prerequisite for any consistency improvement, whether manual or automated. From there, establishing a controlled terminology glossary and introducing a cross-document review gate before submission will reduce the most common inconsistency risks in the short term.

For teams already using CAPTIS®, regular use of the platform’s reporting dashboards to cross-reference surveillance data against CER conclusions, ahead of each PSUR cycle, converts what is often a reactive correction exercise into a proactive quality control step.

Data Consistency as a Competitive Advantage

Organizations that consistently maintain alignment across CERs, PMCF reports, PMS reports, PSURs, SSCPs, and technical documentation are often better positioned for efficient Notified Body reviews. Consistency not only reduces the likelihood of queries and review cycles but also improves internal operational efficiency, particularly for manufacturers managing large portfolios or annual maintenance activities.

As MDR expectations continue to evolve, documentation consistency is becoming an important indicator of regulatory maturity and quality system effectiveness.

Conclusion

Data consistency in EU MDR submissions is ultimately a measure of how well an organisation’s documentation infrastructure reflects its actual device knowledge and clinical evidence. CAPTIS® gives medical device manufacturers and their regulatory writing teams the infrastructure to meet that standard, systematically, reproducibly, and at scale. In a regulatory environment where first-time Notified Body acceptance is both the goal and a genuine competitive advantage, that capability matters.

How Celegence Can Support

Celegence combines deep regulatory expertise with CAPTIS®, our AI-enabled regulatory authoring platform, to help manufacturers strengthen consistency, improve traceability, and streamline MDR documentation activities across the product lifecycle.

Our teams support:

• Clinical Evaluation Reports (CERs)
• Clinical Evaluation Plans (CEPs)
• PMCF Plans and Reports
• PMS Reports
• PSURs
• SSCPs
• Systematic Literature Reviews (SLRs)
• State of the Art (SoTA) evaluations

Whether you are preparing an initial MDR submission, maintaining an existing device portfolio, or responding to Notified Body observations, Celegence can help establish a more efficient and scalable documentation process.

Contact us at info@celegence.com to learn more about CAPTIS® and our MDR compliance services.